Anavex Presents New Data on Preclinical Development of ANAVEX 3-71

Results Demonstrate Significant Reversal in Cognitive Deficit, Inflammation and Alzheimer’s-like Amyloid Pathology NEW YORK, NY – March 14, 2016 – Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various…